BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 2311645)

  • 1. Complement activation by immunoglobulin does not depend solely on C1q binding.
    Bindon CI; Hale G; Waldmann H
    Eur J Immunol; 1990 Feb; 20(2):277-81. PubMed ID: 2311645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
    Bindon CI; Hale G; Waldmann H
    Eur J Immunol; 1988 Oct; 18(10):1507-14. PubMed ID: 2973413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilymphocytic antibodies and marrow transplantation. XIV. Antibody-induced suppression of graft-versus-host disease in C3-decomplemented mice differentiates two T-cell-depletion pathways.
    Thierfelder S; Mysliwietz J; Hoffmann-Fezer G; Kummer U
    Blood; 1991 May; 77(10):2285-91. PubMed ID: 2029584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
    Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
    J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rat polymeric IgA binds C1q, but does not activate C1.
    Hiemstra PS; Rits M; Gorter A; Stuurman ME; Hoekzema R; Bazin H; Vaerman JP; van Es LA; Daha MR
    Mol Immunol; 1990 Sep; 27(9):867-74. PubMed ID: 2215479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
    Bindon CI; Hale G; Brüggemann M; Waldmann H
    J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
    Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
    J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of rat IgM to IgG hybridoma isotype switch variants and analysis of the efficiency of rat Ig in complement activation.
    Pluschke G; Bordmann G; Daoudaki ME; Lambris JD; Achtman M; Neibert M
    Eur J Immunol; 1989 Jan; 19(1):131-5. PubMed ID: 2646134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of fluid phase C1/C1q and macrophage membrane-associated C1q with gram-negative bacteria.
    Clas F; Euteneuer B; Stemmer F; Loos M
    Behring Inst Mitt; 1989 Jul; (84):236-54. PubMed ID: 2552981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
    Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
    Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
    Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
    Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune complex mediated activation of the classical complement pathway.
    Borsos T
    Behring Inst Mitt; 1989 Jul; (84):93-101. PubMed ID: 2478118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.